Donor leukocyte infusions in recurrent Hodgkin lymphoma following allogeneic stem cell transplant: 10-year experience at the M. D. Anderson Cancer Center

Leukemia and Lymphoma

Volumn 53, Issue 6, 2012, Pages 1239-1241

  Anderlini, Paolo ^a   Saliba, Rima ^a   Acholonu, Sandra ^a   Okoroji, Grace Julia ^a   Ledesma, Celina ^a   Andersson, Borje S ^a   Jones, Roy ^a   Popat, Uday R ^a   Hosing, Chitra M ^a   Nieto, Yago ^a   Qazilbash, Muzaffar H ^a   Ueno, Naoto T ^a   Giralt, Sergio A ^b   De Lima, Marcos J ^a   Champlin, Richard E ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; BRENTUXIMAB VEDOTIN; CYCLOPHOSPHAMIDE; FLUDARABINE; MELPHALAN; PANOBINOSTAT; THYMOCYTE ANTIBODY;

ALLOGENEIC STEM CELL TRANSPLANTATION; CANCER MORTALITY; CANCER RECURRENCE; CANCER SURVIVAL; DONOR LYMPHOCYTE INFUSION; HODGKIN DISEASE; HUMAN; LETTER; PRIORITY JOURNAL; PROGNOSIS; SALVAGE THERAPY; TREATMENT RESPONSE;

ADULT; BLOOD DONORS; CANCER CARE FACILITIES; FEMALE; HODGKIN DISEASE; HUMANS; LEUKOCYTE TRANSFUSION; MALE; MIDDLE AGED; RECURRENCE; RETROSPECTIVE STUDIES; SALVAGE THERAPY; STEM CELL TRANSPLANTATION; TEXAS; TIME FACTORS; TRANSPLANTATION, HOMOLOGOUS; YOUNG ADULT;

EID: 84861409241     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2011.644547     Document Type: Letter

References (12)

1. Greaves PJ, Gribben JG. Demonstration of durable graft versus lymphoma Effects in Hodgkin ' s lymphoma. J Clin Oncol 2011;29:952-953.
2. Peggs KS, Hunter A, Chopra R, et al. Clinical evidence of a graft-versus-lymphoma Effect after reduced-intensity allogeneic transplantation. Lancet 2005;365:1906-1908.
3. Porter DL, Stadtmauer EA, Lazarus HM. " G VHD" : graft-versushost disease or graft-versus-Hodgkin ' s disease? An old acronym with new meaning. Bone Marrow Transplant 2003;31:739-746. (Pubitemid 36656665)
4. Peggs KS, Anderlini P, Sureda A. Allogeneic transplantation for Hodgkin lymphoma. Br J Haematol 2008;143:468-480.
5. Robinson SP, Sureda A, Canals C, et al. Reduced-intensity conditioning allogeneic stem cell transplantation for Hodgkin ' s lymphoma: identification of prognostic factors predicting outcome. Haematologica 2009;94:230-238.
6. Peggs KS, Kayani I, Edwards N, et al. Donor lymphocyte infusions modulate relapse risk in mixed chimeras and induce durable salvage in relapsed patients after T-cell-depleted allogeneic transplantation for Hodgkin ' s lymphoma. J Clin Oncol 2011;29:971-978.
7. Peggs KS, Sureda A, Qian W, et al. Reduced-intensity conditioning for allogeneic haematopoietic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: impact of alemtuzumab and donor lymphocyte infusions on long-term outcome. Br J Haematol 2007;139:70-80. (Pubitemid 47389932)
8. Anderlini P, Acholonu SA, Okoroji GJ, et al. Donor leukocyte infusions in relapsed Hodgkin ' s lymphoma following allogeneic stem cell transplantation: CD3-cell dose, GVHD and disease response. Bone Marrow Transplant 2004;34:511-514. (Pubitemid 39264041)
9. Anderlini P, Saliba R, Acholonu S, et al. Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin ' s lymphoma: the updated M.D. Anderson Cancer Center experience. Haematologica 2008;93:257-264. (Pubitemid 351397714)
10. Younes A, Bartlett NL, Leonard JP, et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 2010;363:1812-1821.
11. Sureda A, Engert A, Browett PJ, et al. Interim results for the phase II study of panobinostat (LBH589) in patients with relapsed/ refractory Hodgkin ' s lymphoma (HL) after autologous hematopoietic stem cell transplant (AHSCT). J Clin Oncol 2010;28(15 Suppl.): Abstract 8007.
12. Gopal AK, Ramchandren R, Berryman RB, et al. Brentuximab vedotin (SGN-35) treatment in relapsed CD30-positive Hodgkin lymphoma patients following allogeneic stem cell transplant: a multi-centre case series. Bone Marrow Transpl 2011;46(Suppl. 1): Abstract O267.